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Abstract
Background: In genetically modified (GM) crops there is a risk that the inserted genes may introduce new
allergens and/or adjuvants into the food and feed chain. The MON810 maize, expressing the insecticidal
Cry1Ab toxin, is grown in many countries worldwide. In animal models, intranasal and intraperitoneal immunisations
with the purified Cry1Ab proteins have induced immune responses, and feeding trials with Cry1Ab-containing feed
have revealed some altered immune responses. Previous investigations have primarily measured antibody responses
to the protein, while investigations of clinical food allergy symptoms, or allergy promotion (adjuvant effect) associated
with the Cry1Ab protein are largely missing. We aimed to investigate immunogenic, allergenic and adjuvant properties
of purified Cry1Ab toxin (trypCry1Ab, i.e., trypsin activated Cry1Ab) in a mouse model of food allergy.
Method: Female C3H/HeJ mice were immunized by intragastric gavage of 10 μg purified, trypsin activated Cry1Ab toxin
(trypCry1Ab) alone or together with the food allergen lupin. Cholera toxin was added as a positive control for adjuvant
effect to break oral tolerance. Clinical symptoms (anaphylaxis) as well as humoral and cellular responses were assessed.
Results: In contrast to results from previous airway investigations, we observed no indication of immunogenic
properties of trypCry1Ab protein after repeated intragastric exposures to one dose, with or without CT as
adjuvant. Moreover, the results indicated that trypCry1Ab given by the intragastric route was not able to promote
allergic responses or anaphylactic reactions against the co-administered allergen lupin at the given dose.
Conclusion: The study suggests no immunogenic, allergenic or adjuvant capacity of the given dose of trypCry1Ab
protein after intragastric exposure of prime aged mice.
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Background
The majority of food and feed products from genetically
modified (GM) plants to date are claimed to be com-
positionally and nutritionally comparable to the parent
crops (with the exception of the introduced traits) [1].
There is, however, a concern that the inserted genes
may constitute a risk of introducing new allergens and/or
adjuvants into the food and feed chain [2–5]. Food allergy
is an important public health problem, with a prevalence
of about 8 % in children and 3 % in adults [6]. In food
allergic individuals, the normal development of oral tol-
erance has been disturbed, resulting in T helper type 2
(Th2) immune responses, IgE sensitization towards the
allergen and a risk of immediate hypersensitivity reactions
upon allergen re-exposure [7]. Adjuvants may contribute
to this break of tolerance by a number of mechanisms
such as increased cell surface expression of major histo-
compatibility complex (MHC) and co-stimulatory and/or
adhesions molecules, and modulated release of cytokines
[8, 9], although the mechanisms are not clarified in detail.
* Correspondence: monica.andreassen@fhi.no
1GenØk - Centre for biosafety, Tromsø, Norway
2Norwegian Institute of Public Health, Oslo, Norway
Full list of author information is available at the end of the article
© 2016 Andreassen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Andreassen et al. BMC Immunology  (2016) 17:10 
DOI 10.1186/s12865-016-0148-x
The food allergic response involves several cell types and
organ systems and can cause severe and sometimes fatal
reactions. The primary treatment of food allergy is avoid-
ance of the offending food items. Obviously, the introduc-
tion into the food chain of GM plants containing new
food allergens or proteins with adjuvant potential is
unwanted and an expressed concern [2].
A processed cry1Ab-gene from the soil bacterium
Bacillus thuringiensis (Bt), coding for a bioactive Cry1Ab
insecticidal toxin, has been inserted into the genome of
the maize event MON810, in order to make these crops
resistant to damage caused by lepidopterans. The Bt bac-
terium produces a Cry1Ab protoxin that will exert toxicity
after activation by enzymatic cleavage in the gut of suscep-
tible lepidopteran species [10]. In the MON810 plant,
however, an already activated version of the toxin is
expressed. The European Food Safety Authority (EFSA)
has concluded that Cry1Ab-containing crops are regarded
safe for human and animal consumption [8]. However,
intranasal (i.n.) and intraperitoneal (i.p.) immunisations
with the purified Cry1Ab proteins have been reported
to elicit immune responses in mice [11] and we have
previously demonstrated capacity of the trypsin activated
Cry1Ab (trypCry1Ab) toxin to elicit specific immuno-
globulin (Ig) E and IgG1 antibodies after i.n. exposure
[12]. Furthermore, feeding trials have revealed inflamma-
tory or immune responses related to the ingestion of
Cry1Ab-containing feed in sensitised fish [13], weaning
and old mice [14], rats [15] and pigs [16]. Previous assess-
ments of Cry1Ab immune effects have mainly focused on
its capacity to provoke cellular and/or humoral responses.
The structurally similar Cry1Ac protein has demonstrated
adjuvant capacity in several studies [17–19]. To our know-
ledge, only three studies have investigated allergic adju-
vant effects of Cry1Ab, reporting no [20, 21] and possible
[22] adjuvant capacity after exposure by airways installa-
tion, feeding and oral gavage, respectively. So far, no
experimental studies have investigated whether Cry pro-
teins have adjuvant properties in relation to clinical food
allergy responses.
In the present work, we investigated whether repeated
exposures to one high dose level of trypCry1Ab may
promote allergic responses (i.e., act as adjuvant) in an
anaphylactic food allergy model in mice. Based on the
same immunization regime by intragastric (i.g.) exposure,
we have also explored immunogenic and allergenic prop-
erties of trypCry1Ab by assessments of specific serum
antibodies as well as intestinal gene expression.
Results
Assessment of adjuvant capacity of trypCry1Ab
Anaphylactic responses
During the 30 min after i.p. challenge with allergen ex-
tract (Lupex) on day 35, the rectal temperature dropped
significantly in mice i.g. immunised with Lupex + CT
and Lupex + CT + trypCry1Ab compared to mice immu-
nised with Lupex or Lupex + trypCry1Ab. There was no
significant difference in rectal temperature between the
Lupex + CT and Lupex + CT + trypCry1Ab immunised
mice, or the Lupex and Lupex + trypCry1Ab immunised
mice (Fig. 1a). Likewise, according to the anaphylactic
score given during the 30 min observation period after
the i.p. challenge with Lupex, the clinical response was
significantly more pronounced in mice gavaged with
Lupex + CT and Lupex + CT + trypCry1Ab, compared to
mice gavaged with Lupex or Lupex + trypCry1Ab. The
mice gavaged with Lupex + CT + trypCry1Ab did not dis-
play a significantly stronger anaphylactic response than
mice gavaged with Lupex + CT, nor did the Lupex + tryp-
Cry1Ab versus Lupex exposed mice (Fig. 1b). Since ani-
mals experiencing strong anaphylactic shock (in particular
Lupex + CT and Lupex + CT + trypCry1Ab) gave limited
volume of blood at the terminal bleed, the number of
blood samples per groups available for measurements of
Fig. 1 Anaphylactic responses in mice. Anaphylactic responses in mice after intragastric (i.g.) gavages with Lupex, Lupex + cholera toxin
(CT), Lupex + CT + trypsinised Cry1Ab (trypCry1Ab), Lupex + trypCry1Ab, and HBSS (control) on days 0, 1, 2, 7, 21, and 28, followed by an
intraperitoneal (i.p.) challenge with Lupex on day 35. Rectal temperature (a) was measured at 0, 15 and 30 min after challenge, and
anaphylactic score (b) were determined continuously during those 30 min. Mouse mast cell protease-1 (MCPT-1) levels (c), a marker for
intestinal anaphylaxis, was measured in serum collected after challenge (day 35). Temperatures are presented as group medians over time,
while anaphylactic scores and serum MCPT-1 concentrations are presented for each individual animal (dots) and as the group median (line). Asterisk (*)
denote groups that are significantly different (p < 0.05) from the Lupex group. The dotted line denotes the upper detection limit of the MCPT-1 assay
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the anaphylaxis marker MCPT-1 were low (Fig. 1c). The
few serum samples in these groups, however, all had high
concentrations of MCPT-1, but this increase did not reach
statistical significance relative to the two negative control
groups due to the low sample numbers. Although not
statistically significant for any of the endpoints, almost
half of the animals in the Lupex + trypCry1Ab group
tended to have a weak anaphylactic score and high
MCPT-1 concentrations.
Serum levels of total IgE and lupin-specific antibodies on
day 34
The serum levels of both total IgE (Fig. 2a) and lupin-
specific IgG1 (Fig. 2b) were significantly higher in mice
gavaged with Lupex + CT and Lupex + CT + trypCry1Ab
than in the control and Lupex groups, i.e., irrespective
of the presence of trypCry1Ab. Neither did the antibody
levels differ between groups receiving Lupex with or
without trypCry1Ab.
Splenocyte secretion of cytokines
After stimulation of cultured spleen cells with 17.2 μg/ml
Lupex for five days, the supernates contained low levels or
levels below the detection limit of the cytokines IL-2, -5,
-13, -10 and IFNγ (data not shown). Stimulation with
5 μg/ml ConA for 72 h induced secretion of IL-2, -5, -13,
-10 and IFNγ cytokines, however, the levels were not sig-
nificantly different between the treatment groups (Fig. 3).
Assessment of immunogenicity of trypCry1Ab
Serum levels of total IgE and Cry1Ab-specific antibodies
Serum levels of total IgE, Cry1Ab-specific IgE and IgG2a
did not significantly differ between the groups exposed
to vehicle (control), trypCry1Ab or trypCry1Ab + CT
(Fig. 4). Cry1Ab-specific IgG1for all individuals were
below the assay limit of detection (data not shown).
Splenocyte secretion of cytokines
Exposure to trypCry1Ab or trypCry1Ab + CT did not
affect the IL-2, -5, -13, -10 and IFNγ cytokine levels
secreted by ConA stimulated splenocytes compared to
the negative control (Fig. 5). After splenocyte stimula-
tion with 17.2 μg/ml Cry1Ab for five days, supernates
contained low levels or levels below the detection limit
of the cytokines (data not shown).
Local effects: gene expression in the small intestine
The expression of the genes HSP70, MCPT-1, IL-6, IL-9
and TNFα in tissue from the small intestines was deter-
mined at termination. Neither between the groups in the
adjuvance set-up (Table 1, Fig. 6a, b, c) nor in the im-
munogenicity set-up (Fig. 6d, e, f ) did expression of
TNFα, HSP70 and IL-6 relative to GUSB (housekeeping
gene) differ between the treatment groups. The expres-
sion of the genes MCPT-1 and IL-9 relative to GUSB
were below the limit of detection (data not shown).
Discussion
We investigated the capacity of a 10 μg dose of tryp-
Cry1Ab protein given repeatedly by peroral gavage to
act as an adjuvant and/or to induce immune responses,
in a mouse model of food allergy. The mucosal adjuvant
CT with or without trypCry1Ab was able to condition
for allergic sensitisation and thus anaphylactic responses
in allergen-challenged mice, while trypCry1Ab at the given
dose did not affect any of the allergy or anaphylaxis
markers included in the adjuvance experiment. Further-
more, there was no indication of an immunogenic potential
for i.g. administered trypCry1Ab in the model and with the
dose employed.
We did not observe any adjuvant capacity of the tryp-
Cry1Ab protein on the clinical anaphylactic endpoints
(i.e., loss in temperature and clinical score) or on sensi-
tisation (total IgE and lupin-specific IgG1), neither when
Fig. 2 Serum levels of total IgE and lupin specific IgG1. Serum levels of total IgE (a) and lupin specific IgG1 (b) in mice after intragastric (i.g.) gavages
with Lupex, Lupex + cholera toxin (CT), Lupex + CT + trypsinised Cry1Ab (trypCry1Ab), Lupex + trypCry1Ab, and HBSS (control) on day 0, 1, 2, 7, 21, and
28. Levels are determined in blood samples drawn at day 34. Results are presented for each individual animal (dots) and as the group median (line).
Asterisk (*) denote groups that are significantly different (p < 0.05) from the Lupex group
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administered with Lupex with or without the tolerance-
breaking CT. Serum MCPT-1, a marker of anaphylaxis
in food allergy mouse models [23, 24], was increased in
half of the animals exposed to Lupex + trypCry1Ab com-
pared to the animals exposed to Lupex or vehicle (control).
The elevated MCPT-1 in these few animals was, however,
not accompanied with any changes in temperature loss,
antibody or cytokine responses after challenge or IgE sensi-
tisation, thus did not seem to be associated with an allergic
or anaphylactic reaction. Further, no increase in MCPT-1
was observed in the groups exposed to trypCry1Ab and
trypCry1Ab +CT (data not shown), indicating that tryp-
Cry1Ab itself was not eliciting a MCPT-1 response. Un-
fortunately, expression of the MCPT-1 gene was not
detectable in the intestinal tissue, and cannot contrib-
ute to confirm or reject the observation in serum. Thus,
it seems reasonable not to regard the increase in serum
MCPT-1 in a few animals as an adverse outcome,
although the possibility that trypCry1Ab with Lupex
elicited local effects in the gastrointestinal tract cannot
Fig. 3 Cytokine levels in spleen cell supernates from Lupin exposed mice. Cytokine IL-2 (a), IL-5 (b), IL-13 (c), IL-10 (d) and IFNγ (e) levels
in supernates of concanavalin A (ConA) stimulated spleen cells from mice intragastrically (i.g.) gavaged with Lupex, Lupex + cholera toxin
(CT), Lupex + CT + trypsinised Cry1Ab (trypCry1Ab), Lupex + trypCry1Ab, and HBSS (control) on day 0, 1, 2, 7, 21, and 28, and intraperitoneal (i.p.) challenged
with Lupex on day 35. Results are presented for each individual animal (dots) and as the group median (line)
Fig. 4 Serum levels of total IgE and Cry1Ab-specific IgE and IgG2a. Serum levels on day 34 of total IgE (a), Cry1Ab-specific IgE (b) and Cry1Ab-specific
IgG2a (c) in mice receiving intragastric (i.g.) gavage with trypsinised Cry1Ab (trypCry1Ab), trypCry1Ab + cholera toxin (CT) and HBSS (control) on days 0,
1, 2, 7, 21, and 28. Results are presented for each individual animal (dots) and as the group median (line)
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be excluded, also in light of previous reports [13]. We
therefore conclude that the single dose of trypCry1Ab
did not act as an adjuvant in the present experiments.
We have recently demonstrated that airway exposure to
different versions of the trypCry1Ab protein did not pro-
mote allergic responses comparable to those observed
with the inclusion of an adjuvant (CT) in mice sensitised
with the allergen ovalbumin (OVA) [25]. Furthermore, a
recent study by Reiner et al. [20] investigated the initiation
and severity of allergic asthma in mice fed a MON810
containing diet, and they were not able to detect any dif-
ferences in eosinophilic airway and lung inflammation,
mucus hypersecretion or OVA-specific antibody produc-
tion, compared to mice given a non-GM diet. Taken to-
gether with the previous study, our present data from a
clinical food allergy model further support the notion that
trypCry1Ab do not promote development of immune re-
sponses towards another allergen, i.e., exerts allergic adju-
vant effect. These findings are also partly in agreement
with a previous investigation of the adjuvant capacity of
trypCry1Ab in a model studying lung effects in orally sen-
sitized animals [22]. As in the present study, the study
showed no detectable effects of Cry1Ab on sensitisation
parameters after intragastric exposure. However, while
we did not see any effect after i.p. allergen challenge,
Guimaraes et al. reported that oral Cry1Ab enhanced
local effects in the lungs after airway peanut challenge.
Observed responses after airway allergen challenge were
early production of leukotrienes in bronchoalveolar lavage
fluid (BALF), and late Th2- and Th17-cytokine production
and eosinophil/neutrophil influx. The methodological
differences in doses, route of challenge and target organ
Fig. 5 Cytokine levels in spleen cells supernates from Cry1Ab exposed mice. Cytokine IL-2 (a), IL-5 (b), IL-13 (c), IL-10 (d) and IFNγ (e) levels in
supernates of concanavalin A (ConA) stimulated spleen cells from mice receiving intragastric (i.g.) gavage with trypsinised Cry1Ab (trypCry1Ab),
trypCry1Ab + cholera toxin (CT) and HBSS (control) on days 0, 1, 2, 7, 21, and 28. Results are presented for each individual animal (dots) and as the
group median (line)
Table 1 Exposure schemes
Effect Group Test solutions i.g.
Days 0, 1, 2, 7, 21,
and 28
Challenge i.p.
Day 35
Number
of mice
Adjuvanticity A Lupex Lupex 13
B Lupex + CT Lupex 13
C Lupex + CT + trypCry1Ab Lupex 13
D Lupex + trypCry1Ab Lupex 13
Vehicle control E HBSS - 11
Immunogenicity F TrypCry1Ab - 11
G TrypCry1Ab + CT - 11
i.g. intragastric, i.p intraperitoneal, Lupex lupin extract, CT cholera toxin
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(lungs versus intestines) do not allow for a direct compari-
son of results on local effects.
In the present study, the trypCry1Ab protein showed
no indications of an immunogenic potential, even when
administered together with a potent adjuvant, as the levels
of Cry1Ab-specific antibody levels in serum were low (IgE
and IgG2a) or below the limit of detection (IgG1) in mice
repeatedly gavaged with a single dose of trypCry1Ab. In
contrast, we previously demonstrated strong Cry1Ab-
specific IgG1 and IgE responses following the i.n. route of
exposure to a lower dose of trypCry1Ab [12]. Others have
also detected the immunogenic potential of Cry1Ab pro-
teins. For example, i.n. and i.p. immunisation with the
trypCry1Ab protein induced production of specific anti-
body responses in mice in a study by Guerrero et al. [11].
Also, in rats fed transgenic Bt rice or feed spiked with the
trypCry1Ab a significant elevation of specific antibodies
was detected [26]. Notably, in that study, specific antibody
responses were induced in all rats, including the control
fed rats, suggesting that the airborne particles or dust
from the Cry1Ab feed and/or the Cry1Ab spiked feed
induced immune responses after inhalation. Hence, the
Kroghsbo study cannot conclude on an immunogenic po-
tential after intragastric exposure to Cry1Ab. Adel-Patient
et al. [27] demonstrated that the i.p. route gave a mixed
Th1/Th2 antibody response towards the purified Cry1Ab
protoxin, while in contrast, i.g. administration of purified
Cry1Ab protoxin or MON810 protein extract did not have
any impact on the humoral immune response in mice.
Thus, although previous investigations suggest that the
Cry1Ab protein may be immunogenic after airway expo-
sures, the present study support the previous observations
that Cry1Ab proteins do not exert these properties after
i.g. exposures. Because proteins that are able to escape the
prototypical degradation in the digestive tract are more
likely to reach the intestinal mucosa and to sensitise the
mucosal immune system [7], stability to digestion is con-
sidered to be one of several tools to assess the allergenic
potential of a protein [28]. Guimaraes et al. [29] used
simulated gastric fluid (SGF) at different pH values and
demonstrated that while Cry1Ab were highly degraded
at pH 1.2, it contained its immunoreactivity at pH 2, sug-
gesting that the specific gastric conditions may influence
the outcome of allergenicity assessments. Nevertheless,
Fig. 6 Gene expressions in the small intestine. Relative quantification of TNFα, HSP70 and IL-6 mRNA in the small intestine of mice receiving
intragastric (i.g.) gavage with Lupex, Lupex + cholera toxin (CT), Lupex + CT + trypsinised Cry1Ab (trypCry1Ab), Lupex + trypCry1Ab, and HBSS
(control) (a, b, c), and with trypCry1Ab, trypCry1Ab + CT and HBSS (control) (d, e, f). Results are presented for each individual animal (dots) and
as the group median (line), and the dotted line denotes the 0-line i.e., no difference relative to the housekeeping gene GUSB
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degradation in the intestinal tract may explain why im-
munogenicity seldom is reported after feeding or i.g.
studies, while other administration routes not involving
similarly efficient degradation cause cellular and humoral
responses.
Induction of allergic immune responses following
mucosal immunisation is usually dependent on the
co-administration of appropriate adjuvants to achieve
the allergy-associated Th2 response [30]. In our food
allergy model this is demonstrated by the necessity for
the allergen to be co-administered with CT to disrupt
the oral tolerance and thus enhance antibody responses
(Fig. 2) and the anaphylactic reactions (Fig. 1) against
the Lupex allergen. For investigations of adjuvant ef-
fects, we chose two approaches. Firstly, to test whether
the trypCry1Ab protein could act as an adjuvant with
similar potency as CT, CT was replaced with the tryp-
Cry1Ab protein. Secondly, to test whether trypCry1Ab
could act as a further adjuvant in susceptible individ-
uals where the oral tolerance already is broken, we also
exposed animals to Lupex + CT + trypCry1Ab. The latter
would allow detection of adjuvants in situations where
other circumstances (i.e., exposure to other immunotoxic
components like particles [31, 32], gastrointestinal infec-
tions or genetic susceptibilities are also in favor of allergy
induction, as for instance reported by Bol-Shoenmakers et
al. [33]. Since this latter approach would also allow detec-
tion of weaker adjuvants, the negative results strengthen
the conclusion that the given dose of trypCry1Ab does not
present adjuvant activity after oral exposure.
The use of the mucosal adjuvant CT in assessment of
allergenicity of novel proteins, however, has been de-
bated. Atkinson and Miller [34] suggest that the use of
CT as adjuvant may compromise the discrimination be-
tween proteins with respect to allergenic potential. We
included the mucosal adjuvant CT together with the
trypCry1Ab protein (Figs. 4, 5 and 6) to disrupt the oral
tolerance, which as described above may happen in real
life. In line with the criteria suggested by Prescott and
Hogan [4] for the assessment of GM foods we also in-
cluded an experimental group without the CT. Overall,
neither of the experimental groups exposed to trypCry1Ab
differed from the respective control group, strengthening
our conclusion of no immunogenic or adjuvant properties
of the trypCry1Ab proteins at the given dose after i.g.
exposure.
In the food allergy models by Vinje et al. [23] and Li
et al. [35], IgE antibodies against lupin and peanut aller-
gens, respectively, were detected in the serum of female
C3H/HeJ mice, and splenocytes demonstrated a mixed
Th1/Th2 cytokine release and proliferative responses
after ex vivo stimulation with allergens in the form of
extracts or purified proteins. In addition, serum MCPT-1
together with high anaphylactic scores indicated the
usefulness as a mouse model for clinical food allergy. In
agreement, the positive control in the present study,
Lupex + CT, also showed increased antibody, MCPT-1
and anaphylactic responses. On the other hand, the cul-
tured spleen cells stimulated with the antigens (lupin or
trypCry1Ab) secreted low or undetectable levels of the
cytokines IL-2, IL-5, IL-13, IL-10 and IFNγ. In the cell
cultures, the antigens were added at much lower dose
than in the original protocol by Vinje et al. [23] (17,2
versus 50 μg) due to practical limitations in the solubil-
ity of trypCry1Ab proteins, which probably explain why
cytokine release were not elevated even in the positive
control (Lupex + CT). Spleen cells stimulated with ConA
(5 μg/ml), as an “unspecific” T cell stimulating mitogen
probably stimulating a much higher proportion of the T
cells, secreted IL-2, IL-5, IL-13, IL-10 and IFNγ cytokines,
however these levels were not different between any of the
treatments. A trend, however not significant, was detected
in the positive control (Lupex + CT) and it may be specu-
lated that the time interval from the latest exposure on
day 28 until the harvest and stimulation of splenocytes on
day 35 did not allow for a robust secretion of cytokines.
To further look for local effects of Cry1Ab in the
intestinal mucosa we assessed the expression of genes
suggested to be involved in the immune response in the
intestinal tissue, as indicated in a study by Gu et al.
[13]. The expression levels were quantified by normalisa-
tion against GUSB, identified as one of the most stable
reference genes in the mouse small intestine, also com-
pared to the commonly used reference gene glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) proving to be
unstable [36]. The present data could not confirm the
alterations in gene expression reported in Gu and co-
workers’ study, where feeding of MON810 maize seemed
to potentiate oxidative cellular stress in the intestine of
sensitised fish, as indicated by increases in superoxide
dismutase and HSP70 mRNA expression. We cannot ex-
clude that the different species, exposure regime, timing
(in our study it was three days since the last Cry1Ab
exposure), or methodological considerations contrib-
uted to the observed lack of local gene expression
changes in our mouse model.
The present study does not indicate adverse health
effects of trypCry1Ab in terms of immunogenic, allergenic
or adjuvant properties, however, there are several experi-
mental limitations that should be considered. The Cry1Ab
protein is expressed at low levels in plant material (6.92
and 612.51 ng/mg Cry1Ab in pollen and leaves, respect-
ively, reported in Andreassen et al. [21]), and methods for
isolation/extraction of plant Cry1Ab protein in sufficient
amounts for this study was not available. Therefore, a re-
combinant version was produced in the E. coli bacteria
and subsequently trypsin digested to “mimic” the activated
form expressed in the plants. This introduces, however, a
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restriction to our conclusions, since trypCry1Ab toxin
may have a different immunomodulation capacity than
the toxin expressed in plant material due to subtle struc-
tural differences. Moreover, oral gavage was chosen as a
model for oral exposure via food, and gives more accurate
dose administrations than exposure via food. However,
the daily bolus administration differs from the real-life sit-
uations where the proteins are consumed in whole foods.
Furthermore, our results from a repeated oral gavage of
one dose level of trypCry1Ab cannot directly be used to
generalise for other doses (or exposure frequencies).
Quantitative maize kernel Cry1Ab-expression data [37]
indicates that the applied dose of 10 μg per mouse per
gavage equals the amount of Cry1Ab expressed in 40 g of
maize kernels, which represent a relatively extreme intake
for these mice that typically consume 4–5 g feed per day.
This high dose was chosen for a proof-of-principle ap-
proach, and since there were no effects observed at this
dose level, no further experiments with lower doses were
performed. As always, caution should be taken to directly
transfer results from mice models to humans. Future re-
search concerning Cry1Ab hazard characterisation, how-
ever, would benefit from use of the plant version of the
Cry1Ab, several doses and/or realistic exposure regimes.
Epidemiological investigations of GMO-safety in general,
and immune system effects in particular, are sparse, and
systematic studies are warranted.
Conclusions
A single test model should not alone be used to prove
or disprove the potential of GM proteins to induce
adverse immune responses. However, taken together,
the present study supports previous findings suggest-
ing no detectable immunogenic, allergenic or adjuvant
capacity of the trypCry1Ab protein after i.g. exposure,
within the limitations of the model, the doses and the
protein contexts applied.
Methods
Animals
Female C3H/HeJ mice (Jackson Laboratories, USA),
5 weeks old at arrival, were randomly allocated to groups
(n = 11–13) and housed on Nestpack bedding (Datesand
Ltd, Manchester, UK), 3–5 mice in each cage. The Harlan
Teklad 2018 rodent diet and tap water were given ad
libitum. The mice were exposed to a 12/12 h light/
dark cycle, room temperature (RT) of 21 +/− 2 °C
and 55 +/− 10 % humidity. The experiment was per-
formed in conformity with the laws and regulations
for live animals in Norway, and approved by the Norwegian
Animal Research Authority under the Ministry of Agricul-
ture (FOTS ID 4534).
TrypCry1Ab protein
TrypCry1Ab toxin was purchased from Case Western
Reserve University, (Ohio, USA, Dr. Marianne Pusztai-
Carey). The origin of the cry1Ab gene inserted in Escher-
ichia coli (E. coli) was the Bt kurstaki HD-1 strain. The
inclusion bodies were solubilised at pH 10.5 in the pres-
ence of a reducing agent and the precipitated protoxins
were digested by commercial bovine trypsin and subse-
quently purified by ion exchange high-performance liquid
chromatography (HPLC). The relevant fractions were ana-
lysed by gel filtration, HPLC and sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE), desalted
and lyophilised (M. Carey, personal communication). The
protein preparations were dissolved in a sterile physio-
logical buffer (Hanks Balanced Salt Solution; HBSS) to a
concentration of 172 μg/ml.
Lupin extract and cholera toxin (CT)
Protein extract from Lupinus angustifolius (Lupex) was
produced and provided by The National Veterinary Insti-
tute of Norway. The extract preparation procedure is
described in Vinje et al. [23], and the protein extract had a
concentration of 72.4 mg/ml. Cholera toxin (CT) from
Vibrio cholerae, azide free, 1 mg/ml solution, was pur-
chased from Quadratech Diagnostics Ltd (Surrey, UK).
Preparation of test solutions
The test solutions were prepared in HBSS and given to
the mice in volumes of 250 μl, resulting in the following
doses per animal per gavage: A; 5.7 mg Lupex, B; 5.7 mg
Lupex + 10 μg CT, C; 5.7 mg Lupex + 10 μg CT + 10 μg
trypCry1Ab, D; 5.7 mg Lupex + 10 μg trypCry1Ab, E;
10 μg trypCry1Ab, F; 10 μg trypCry1Ab + 10 μg CT. The
control solution G consisted solely of 250 μl HBSS. A
high dose of 10 μg trypCry1Ab was selected due to the
proof-of-principle character of the study and in order to
be able to compare a potential adjuvant effect with the
effect induced by 10 μg of the positive control, CT. Re-
strictions in gavage volume (max 250 ml) and the tryp-
Cry1Ab solubility prevented us from giving a higher dose
per animal per exposure.
Experimental design
The mice were exposed by i.g. gavage of 250 μL test
solutions according to Table 1, on days 0, 1, 2, 7, 21, and
28. A 100 μL blood sample was collected from vena
saphena lateralis from each animal on day 0 and 34. On
day 35, to examine the potential adjuvant effect of tryp-
Cry1Ab, a challenge of Lupex was given i.p. to all mice
in the experimental groups A - D according to Table 1,
and the anaphylactic responses were assessed during
30 min following the i.p. challenge (described below). All
mice were anaesthetised with 3.5 % Isofluran gas (Isoba
vet; Intervet/Schering-Plough Animal Health, Lysaker,
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Norway) administered in surgical O2 in an inhalation
chamber before exsanguination by heart puncture, and
blood, spleen and 5 cm of the small intestine (distal
ileum) were harvested.
Assessment of clinical anaphylactic reactions
On day 35, clinical anaphylactic reactions were assessed
continuously in 30 min directly after an i.p. challenge
with 250 μl of HBSS containing 5 mg of the allergen. The
score system described by Li et al. [35] was employed: 0,
no symptoms; 1, scratching and rubbing around the nose
and head; 2, puffiness around the eyes and mouth, diar-
rhoea, pili erecti, inactivity or decreased activity with an
increased respiratory rate; 3, wheezing, laboured respir-
ation, cyanosis around the mouth and tail; 4, no activity
after prodding or tremor or convulsion; and 5, death. Rec-
tal temperature was measured after 0, 15 and 30 min with
a BAT-12 microprobe thermometer (probe RET-3) pur-
chased from Physitemp Instruments Inc (Clifton, USA).
The mice were exsanguinated by terminal heart bleed
immediately after the 30 min observation period, or when
reaching a score of 4 or above.
Measurement of serum mouse mast cell protease-1
(MCPT-1)
As a marker of anaphylaxis, serum levels of mouse mast
cell protease-1 (MCPT-1) were analysed in terminal
blood samples collected after allergen challenge, with
an enzyme-linked immunosorbent assay (ELISA) kit
(Moredun Scientific Ltd., Scotland, UK) in accordance
with the manufacturer’s instructions.
Detection of lupin-specific antibodies
The detection of lupin-specific IgG1 antibodies was per-
formed according to Vinje et al. [23]. In brief; microtiter
plates with 96 wells were coated with lupin extract
(5 μg/ml), incubated for 1 h at room temperature (RT)
and then overnight at 4 °C. After washing (Tris/Tween),
blocking (Tris/Tween with 1 % bovine serum albumin) for
1 h, and subsequent washing, plates were incubated for
2 h at RT with lupin-specific IgG1 standard serum in four-
fold dilutions for standard curve generation, negative con-
trol serum and the sera collected at day 34 (diluted 1:100
in BSA/Tris/Tween). After washing, peroxidase-labelled
rat anti-mouse IgG1 antibody was added to each well. Fol-
lowing 2 h incubation at RT, and washing, plates were
incubated for 15 min with peroxidase substrate. Plates
were read at 405 nm in a BioTek Elx808 Absorbance
Microplate reader using Gen5™ Microplate Data Collec-
tion & Analysis Software (BioTek® Instruments, Inc.,
Winooski, Vermont, USA).
Detection of Cry1Ab-specific antibodies
In-house ELISA protocols were established to detect spe-
cific anti-Cry1Ab IgG1, IgG2a and IgE antibodies in the
mouse sera as previously described in Andreassen et al.
In brief, for the IgG1 assay, 96-well microtiter plates
were coated with 2 ng/μL purified trypCry1Ab protein
per well and incubated for 1 h at RT and then overnight
at 4 °C. Plates were washed (Tris/Tween) and incubated
with blocking solution (5 % skimmed milk powder in
phosphate buffered saline (PBS)) for 1 h at RT. After
subsequent washing, diluted sera (1:50) from terminal
blood samples were added and plates were incubated for
1 h at RT and again overnight at 4 °C. The plates were
washed, 200 ng biotinylated rat anti-mouse IgG1 was
added per well and plates were incubated for 1 h at RT.
After subsequent washing, poly-horseradish peroxidase
(HRP)-streptavidin diluted 1:40000 was added and incu-
bated for 1 h at RT. The plates were washed and color
development was obtained by adding stabilised chromogen
3,3′, 5,5;-tetramethylbenzidine (TBM). After incubation in
darkness for maximum 15 min the reaction was stopped
with 2 N H2SO4 solution.
For detection of Cry1Ab-specific IgE, microtiter plates
with 96 wells were coated with 200 ng rat anti mouse
IgE antibodies per well, incubated for 1 h at RT and then
overnight at 4 °C. Subsequently, the plates were washed
with Tris/Tween and blocked with 5 % skimmed milk in
PBS for 1 h at RT. After subsequent washing, diluted
sera (1:10) from blood sampled at day 34 were added
and plates were incubated for 1 h at RT and then again
overnight at 4 °C. The plates were washed, 300 ng tryp-
Cry1Ab was added to each well and incubated for 1 h at
RT. After subsequent washing, 300 ng biotinylated rabbit
anti mouse Cry1Ab antibody was added per well as
detection antibody and plates were incubated for 1 h at
RT. Plates were washed and detection was performed
with poly-HRP-streptavidin and stabilised chromogen
TBM as described above. The reaction was stopped with
2 N H2SO4 solution after incubation in the dark for a
maximum of 15 min.
For detection of Cry1Ab-specific IgG2a, microtiter
plates with 96 wells were coated with 200 ng biotinyl-
ated rat anti mouse IgG2a antibodies per well, and the
protocol for Cry1Ab-specific IgE detection was subse-
quently followed as described above. To accelerate the
reactivity of each step, all incubations were performed at
37 °C for the detection of specific anti-Cry1Ab IgG2a.
Standard curves were made from duplicates of diluted
serum pools from mice (repeatedly i.p.) immunised with
trypCry1Ab and Al(OH)3, and included for all antibody
assays on each plate. As the amount of specific IgG1,
IgE and IgG2a in the standards is unknown, the levels
are presented as arbitrary units (AU) per ml serum. Ab-
sorbance was measured at 450 nm on a BioTek Elx808
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Absorbance Microplate reader with the Gen5™ Micro-
plate Data Collection & Analysis Software (BioTek®
Instruments, Inc., Winooski, Vermont, USA).
Total IgE
Serum levels of total IgE were analysed in blood samples
from day 34, using a Mouse IgE ready-set-go ELISA-kit
(Affymetrix eBioscience, Vienna, Austria) in accordance
to the manufacturer’s instructions.
Splenocyte preparation and cytokine measurement
The excised spleens were crushed through a 70 μm cell
strainer (BD labware, New Jersey, USA) to obtain single
cell suspensions as described previously [38]. Cell num-
bers were determined with a Cell Coulter Z1 (Beckman
Coulter Inc., Florida, USA). Cells were cultured in medium
(RPMI 1640 with L-glutamine and 10 % foetal bovine
serum and 1 % streptomycin/penicillin) in 96 well plates at
a concentration of 2.7 × 106 cells/ml per well at 37 °C in a
humidified atmosphere with 5 % CO2 for three days with
concanavalin A (ConA) (5 μg/ml), and for five days with or
without Lupex or trypCry1Ab (17.2 μg/mL). The total vol-
ume in each well was 200 μl. The amount of cytokine IL-2,
IL-5, IL-13, IL-10, and interferon gamma (IFNγ) released
into spleen cell supernates were determined by Cytometric
Bead Array (CBA) flex set kit from BD Biosciences (San
Diego, California, USA).
Gene expression in the small intestine
A 5 cm segment of ileum were excised (7 to 12 cm from
the cecum), flushed thorough with PBS, cut into smaller
fractions and put in a cryogenic vial that was snap frozen
in liquid nitrogen and kept at –80 °C for later preparation
and quantitative polymerase chain reaction (PCR) ana-
lyses. Frozen tissue segments were dissected with a scalpel
on dry ice. Tissue segments between 14.3 and 68.8 mg
were homogenised in a tube containing hard tissue CK28
beads (Bertine technologies, France) and 250 μL lysis
buffer with 1.75 μL β-mercaptoethanol (Absolutely RNA
Miniprep Kit, Agilent Technologies La Jolla, California),
in a Precellys 24 homogeniser (Bertine Technologies,
France) for 2 × 46 s at RT. Total RNA was extracted using
Absolutely RNA Miniprep Kit (Agilent Technologies La
Jolla, California) according to the manufacturer’s in-
structions. To assess yield and quality, the total RNA
extract was evaluated using a Nandodrop spectropho-
tometer (Thermo scientific Wilmington, Denver, USA)
and subsequently the RNA Integrity Number (RIN) was
determined using a 2100 Bioanalyzer (Agilent Tech-
nologies La Jolla, California). Samples with RIN number
lower than 4.8 were considered to be of poor quality
and were not included in the following steps. First-
strand cDNA synthesis of 50 ng total RNA were per-
formed using a master mix containing 1xfirst strand
MM buffer, 225 ng oligo(dT), 45 ng random hexamer and
AffinityScriptRT/RNase block enzyme mixture (1.5 μL/
30 μL total volume) and distilled water to a total volume
of 30 μL (Agilent Technologies La Jolla, California). The
syntheses were performed with a Bio Rad S1000 Thermal
Cycler (Bio Rad Laboratories California, USA). The syn-
theses condition was 25 °C for 5 min, 42 °C for 30 min,
95 °C for 5 min and 12 °C for infinite. Real-Time PCR was
performed by adding 1.0 μL cDNA solution to a master
mix containing 1xPrimeTime assay (containing a probe
and two primers), 1xBrilliant III Ultra-Fast QPCR Master
Mix, 0.45 ng Reference dye and water to a total volume of
20 μL (Agilent Technologies La Jolla, California). The
real-time PCR was performed with an Applied Biosystems
7500 Fast Real-Time PCR Systems (Applied Biosystems
life technology, Thermo Scientific Waltham, Massachusetts,
USA). The amplification conditions were 95 °C for 3 min,
followed by 40 cycles at 95 °C for 20 s and 60 °C for 30 s.
In total there were seven PrimeTime assays, five target
genes; heat shock protein (HSP) 70 (primer 1: 5’-GTAGTA
CACAGTGCCAAGACG-3’, primer 2: 5’-TTTATATCAG
TGTTCCAGTAGCCT-3’), MCPT-1 (primer 1: 5’-ACTCA
ACACCACCAATAATCTCC-3’, primer 2: 5’-GGAACCA
GGACAAGAACACA-3’), IL-6 (primer 1: 5’-CAAGTGCA
TCATCGTTGTTCA-3’, primer 2: 5’-GATACCACTCCC
AACAGACC-3’), IL-9 (primer 1: 5’-GCAGCTGGTCA
CGTTGC-3’, primer 2: 5’-CTTGCCTCTGTTTTGCTC
TTC -3’), and tumour necrosis factor (TNF)α (primer 1: 5’-
TCTTTGAGATCCATGCCGTTG-3’, primer 2: 5’-AGAC
CCTCACACTCAGATCA-3’), and two reference genes;
TATA box binding protein (Tbp) (primer 1: 5’-CTGAAT
AGGCTGTGGAGTAACTC-3’, primer 2: 5’-CTGAAGA
AAGGGAGAATCATGGA-3’) and glucuronidase-beta
(GUSB) (primer 1: 5’-GATGCGTCTTATACCAGTTC
TCA-3’, primer 2: 5’-CAACGCCAAATATGATGCA
GAC-3’). The threshold cycle number (Ct) was determined
with ABI 7500 software from Applied Biosystems life tech-
nology (Thermo Scientific Waltham, Massachusetts, USA).
Gene expression levels were normalised by subtraction of
the housekeeping gene GUSB Ct from target gene Ct, and
then against the calibrator (= ΔΔCt). To obtain positive
values for upregulated genes and negative values for down-
regulated genes, all ΔΔCt values were multiplied with −1.
Statistical analyses
Statistical analyses were performed with Sigma Plot 12.3
and Minitab 16 Statistical software. All normally distributed
data with equal variance were tested by one way ANOVA.
If significant overall differences were found, pairs of treat-
ments were then tested with a Tukey adjusted post hoc test.
Data that could not be transformed to normal distribution
and comparable variance by log10 transformation were
tested with the non-parametric Kruskal-Wallis test, while
the Mann–Whitney post hoc test was used to evaluate
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differences between pairs of treatments. Differences
between treatments were considered significant when
p-values were below 0.05.
Ethics approval
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approved by the Norwegian Animal Research Authority
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Availability of data and material
The datasets supporting the conclusions of this article
are included within the article (and its Additional file 1
“FOTS 4534_all datasets”).
Additional file
Additional file 1: The Excel datafile “FOTS 4534_all datasets” includes
all datasets supporting the conclusions of this article: Clinical endpoints,
serum MCPT-1, serum total IgE, serum lupin-specific IgG1, splenocyte IL-2,
IL-5, IL-10, IL-13 and IFNγ, serum Cry1Ab-specific IgE, IgG1 and IgG2a,
and gene expression of TNFα, Hsp70 and IL-6 in the small intestine.
(XLSX 124 kb)
Abbreviations
Bt: Bacillus thuringiensis; CT: cholera toxin; GM: genetically modified;
i.g.: intragastric; Lupex: lupin extract; trypCry1Ab: trypsin activated Cry1Ab.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MA participated in the design of the study, carried out the animal study
and the laboratory and the statistical analysis, and drafted the manuscript.
TB, OGW, ML and TT participated in the design of the study and helped
to interpret the data and critically revised the manuscript. JB contributed
substantially with the animal experiment and critically revised the
manuscript. UCN participated in the study design, animal experiment and
statistical analysis, and helped to draft and critically revise the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We are grateful for the help and technical skills of Åse Eikeset, Bodil
Hasseltvedt, Berit Stensby, Else-Carin Groeng, Astri Grestad, Hege Hjertholm,
Tone Rasmussen, Trude Olsen, Kari Løken and Henrik Rasmussen at
Norwegian Institute of Public Health.
Funding
The study was funded by GenØk – centre for biosafety and the Norwegian
Institute of Public Health.
Author details
1GenØk - Centre for biosafety, Tromsø, Norway. 2Norwegian Institute of
Public Health, Oslo, Norway. 3UiT The Arctic University of Norway, Tromsø,
Norway. 4North West University, Potchefstroom, South Africa. 5Norwegian
University of Science and Technology, Trondheim, Norway. 6Present address:
Department of Food, Water and Cosmetics, Norwegian Institute of Public
Health, PO Box 4404, 0403 Oslo, Norway.
Received: 4 July 2015 Accepted: 28 April 2016
References
1. EFSA. Safety and nutritional assessment of GM plants and derived food and feed:
the role of animal feeding trials. Food Chem Toxicol. 2008;46 Suppl 1:S2–70.
2. EFSA. Scientific opinion on the assessment of allergenicity of GM plants and
microorganisms and derived food and feed. Panel on genetically modified
organisms. EFSA J. 2010;8(7):1700. [168 pp]. 2010.
3. Bernstein JA, Bernstein IL, Bucchini L, Goldman LR, Hamilton RG, Lehrer S,
Rubin C, Sampson HA. Clinical and laboratory investigation of allergy to
genetically modified foods. Environ Health Perspect. 2003;111(8):1114–21.
4. Prescott VE, Hogan SP. Genetically modified plants and food hypersensitivity
diseases: usage and implications of experimental models for risk
assessment. Pharmacol Ther. 2006;111(2):374–83.
5. Kimber I, Dearman RJ. Approaches to assessment of the allergenic potential of
novel proteins in food from genetically modified crops. Toxicol Sci. 2002;68(1):4–8.
6. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis,
and treatment. J Allergy Clin Immunol. 2014;133(2):291–307. quiz 308.
7. Steele L, Mayer L, Berin MC. Mucosal immunology of tolerance and allergy
in the gastrointestinal tract. Immunol Res. 2012;54(1-3):75–82.
8. EFSA. Scientific Opinion of the Panel on Genetically Modified Organisms.
Applications (EFSA-GMO-RX-MON810) for renewal of authorisation for the
continued marketing of (1) existing food and food ingredients produced
from genetically modified insect resistant maize MON810; (2) feed
consisting of and/or containing maize MON810, including the use of seed
for cultivation; and of (3) food and feed additives, and feed materials
produced from maize MON810, all under Regulation (EC) No 1829/2003
from Monsanto. EFSA J. 2009;1149:1–85.
9. Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and
experimental adjuvants–a brief overview. Immunol Lett. 2010;128(1):29–35.
10. Bravo A, Gill SS, Soberon M. Mode of action of Bacillus thuringiensis Cry and
Cyt toxins and their potential for insect control. Toxicon. 2007;49(4):423–35.
11. Guerrero GG, Dean DH, Moreno-Fierros L. Structural implication of the
induced immune response by Bacillus thuringiensis Cry proteins: role of the
N-terminal region. Mol Immunol. 2004;41(12):1177–83.
12. Andreassen M, Rocca E, Bøhn T, Wikmark O-G, van den Berg J, Løvik M,
Traavik T, Nygaard UC. Humoral and cellular immune responses in mice
after airway administration of Bacillus thuringiensis Cry1Ab and MON810
cry1Ab-transgenic maize. Food Agric Immunol. 2014;26(4)1–17.
13. Gu J, Krogdahl A, Sissener NH, Kortner TM, Gelencser E, Hemre GI,
Bakke AM. Effects of oral Bt-maize (MON810) exposure on growth and
health parameters in normal and sensitised Atlantic salmon, Salmo salar
L. Br J Nutr. 2013;109(8):1408–23.
14. Finamore A, Roselli M, Britti S, Monastra G, Ambra R, Turrini A, Mengheri E.
Intestinal and peripheral immune response to MON810 maize ingestion in
weaning and old mice. J Agric Food Chem. 2008;56(23):11533–9.
15. Knudsen I, Poulsen M. Comparative safety testing of genetically modified
foods in a 90-day rat feeding study design allowing the distinction between
primary and secondary effects of the new genetic event. Regul Toxicol
Pharmacol. 2007;49(1):53–62.
16. Walsh MC, Buzoianu SG, Gardiner GE, Rea MC, Gelencser E, Janosi A,
Epstein MM, Ross RP, Lawlor PG. Fate of transgenic DNA from orally
administered Bt MON810 maize and effects on immune response and
growth in pigs. PLoS ONE. 2011;6(11):e27177.
17. Vazquez RI, Moreno-Fierros L, Neri-Bazan L, De La Riva GA, Lopez-Revilla R.
Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal
adjuvant. Scand J Immunol. 1999;49(6):578–84.
18. Moreno-Fierros L, Ruiz-Medina EJ, Esquivel R, Lopez-Revilla R, Pina-Cruz S.
Intranasal Cry1Ac protoxin is an effective mucosal and systemic carrier and
adjuvant of Streptococcus pneumoniae polysaccharides in mice. Scand J
Immunol. 2003;57(1):45–55.
19. Moreno-Fierros L, Garcia-Hernandez AL, Ilhuicatzi-Alvarado D, Rivera-Santiago L,
Torres-Martinez M, Rubio-Infante N, Legorreta-Herrera M. Cry1Ac protoxin from
Bacillus thuringiensis promotes macrophage activation by upregulating CD80
and CD86 and by inducing IL-6, MCP-1 and TNF-alpha cytokines. Int
Immunopharmacol. 2013;17(4):1051–66.
20. Reiner D, Lee RY, Dekan G, Epstein MM. No adjuvant effect of Bacillus
thuringiensis-maize on allergic responses in mice. PLoS ONE. 2014;9(8), e103979.
21. Andreassen M, Bohn T, Wikmark OG, Van den Berg J, Lovik M, Traavik T,
Nygaard UC. Cry1Ab protein from Bacillus thuringiensis and MON810
cry1Ab-transgenic maize exerts no adjuvant effect after airway exposure.
Scand J Immunol. 2015;81(3):192–200.
22. Guimaraes VD, Drumare MF, Ah-Leung S, Lereclus D, Bernard H, Creminon C,
Wal JM, Adel-Patient K. Comparative study of the adjuvanticity of Bacillus
thuringiensis Cry1Ab protein and cholera toxin on allergic sensitisation and
elicitation to peanut. Food Agric Immunol. 2008;19(4):325–37.
Andreassen et al. BMC Immunology  (2016) 17:10 Page 11 of 12
23. Vinje NE, Larsen S, Lovik M. A mouse model of lupin allergy. Clin Exp
Allergy. 2009;39(8):1255–66.
24. Vaali K, Puumalainen TJ, Lehto M, Wolff H, Rita H, Alenius H, Palosuo T.
Murine model of food allergy after epicutaneous sensitization: role of
mucosal mast cell protease-1. Scand J Gastroenterol. 2006;41(12):1405–13.
25. Andreassen M, Bohn T, Wikmark OG, Van den Berg J, Lovik M, Traavik T,
Nygaard UC. Cry1Ab protein from Bacillus thuringiensis and MON810
cry1Ab-transgenic maize exerts no adjuvant effect after airway exposure.
Scand J Immunol. 2015;81(3):192-200.
26. Kroghsbo S, Madsen C, Poulsen M, Schroder M, Kvist PH, Taylor M,
Gatehouse A, Shu Q, Knudsen I. Immunotoxicological studies of genetically
modified rice expressing PHA-E lectin or Bt toxin in Wistar rats. Toxicology.
2008;245(1-2):24–34.
27. Adel-Patient K, Guimaraes VD, Paris A, Drumare MF, Ah-Leung S,
Lamourette P, Nevers MC, Canlet C, Molina J, Bernard H, et al.
Immunological and metabolomic impacts of administration of Cry1Ab
protein and MON 810 maize in mouse. PLoS ONE. 2011;6(1):e16346.
28. Moreno FJ. Gastrointestinal digestion of food allergens: effect on their
allergenicity. Biomed Pharmacother. 2007;61(1):50–60.
29. Guimaraes V, Drumare MF, Lereclus D, Gohar M, Lamourette P, Nevers MC,
Vaisanen-Tunkelrott ML, Bernard H, Guillon B, Creminon C, et al. In vitro
digestion of Cry1Ab proteins and analysis of the impact on their
immunoreactivity. J Agric Food Chem. 2010;58(5):3222–31.
30. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin
Immunol. 2007;120(3):506–15. quiz 516-507.
31. Nygaard UC, Aase A, Lovik M. The allergy adjuvant effect of particles -
genetic factors influence antibody and cytokine responses. BMC Immunol.
2005;6:11.
32. Alberg T, Hansen JS, Lovik M, Nygaard UC. Particles influence allergic
responses in mice–role of gender and particle size. J Toxic Environ Health A.
2014;77(5):281–92.
33. Bol-Schoenmakers M, Bleumink R, Marcondes Rezende M, Mouser E,
Hassing I, Ludwig I, Smit JJ, Pieters RH. Diclofenac enhances allergic responses
in a mouse peanut allergy model. Clin Exp Allergy. 2011;41(3):424–33.
34. Atkinson HA, Miller K. Assessment [correction of Asessment] of the brown
Norway rat as a suitable model for the investigation of food allergy.
Toxicology. 1994;91(3):281–8.
35. Li XM, Serebrisky D, Lee SY, Huang CK, Bardina L, Schofield BH, Stanley JS,
Burks AW, Bannon GA, Sampson HA. A murine model of peanut
anaphylaxis: T- and B-cell responses to a major peanut allergen mimic
human responses. J Allergy Clin Immunol. 2000;106(1 Pt 1):150–8.
36. Wang F, Wang J, Liu D, Su Y. Normalizing genes for real-time polymerase
chain reaction in epithelial and nonepithelial cells of mouse small intestine.
Anal Biochem. 2010;399(2):211–7.
37. Nguyen H, Jehle J. Quantitative analysis of the seasonal and tissue-specific
expression of Cry1Ab in transgenic maize Mon810. J Plant Dis Protect.
2007;114(2):82–7.
38. Hansen JS, Alberg T, Rasmussen H, Lovik M, Nygaard UC. Determinants of
experimental allergic responses: interactions between allergen dose, sex
and age. Scand J Immunol. 2011;73(6):554–67.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Andreassen et al. BMC Immunology  (2016) 17:10 Page 12 of 12
